Q2 2026 saw strong sales and margin expansion, with net sales up 13.8% and adjusted EPS up 28.8% year-over-year. Full-year guidance for both net sales and EPS was raised, driven by robust growth in High Value Product Components and Biologics.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.